Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021

Events, News, Presentations, Press Releases

Fred Hutchinson Cancer Research Center, in Partnership with Sutro Biopharma, to Present at ASH 2021 – Nonclinical data for STRO-002 and STRO-001 are shared in two oral presentations at the 63rd American Society of Hematology Annual Meeting SOUTH SAN FRANCISCO, Calif,...

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in the 2021 Wells Fargo Virtual Healthcare Conference SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of...

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones

News, Press Releases

Sutro Biopharma Reports Second Quarter 2021 Financial Results, Business Highlights and Anticipated Second Half 2021 Milestones – Additional follow-up data on STRO-002 from the Phase 1 dose-escalation cohort were presented at ASCO June 2021; enrollment for the...

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

News, Press Releases

Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares South San Francisco, Calif., May 14, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery,...

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering

News, Press Releases

Sutro Biopharma Announces Pricing of $85.3 Million Public Offering South San Francisco, Calif., May 11, 2020 – Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical stage drug discovery, development and manufacturing company focused on deploying its proprietary integrated...
« Older Entries

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080

Phone: 650-881-6500

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2026 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY  | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

 

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.